Buclizine for Appetite Stimulation in Elderly Patients
Buclizine should not be used as an appetite stimulant in elderly patients because there is no evidence supporting its efficacy for this indication, and it carries significant anticholinergic risks that are particularly dangerous in older adults.
Evidence Base for Appetite Stimulation
No guideline or clinical trial supports buclizine as an appetite stimulant. The drug is classified as an antihistamine with antimuscarinic and antiemetic properties, primarily used for motion sickness and migraine prevention 1, 2. While one research paper mentions buclizine has been "reintroduced as an appetite stimulant, especially for pediatric patients" 3, this claim appears in a pharmaceutical chemistry study with no clinical evidence cited, and no major clinical guidelines reference this use.
Why Buclizine Is Inappropriate for Elderly Patients
Anticholinergic Burden
Buclizine has potent anticholinergic effects that pose serious risks in geriatric populations 1:
- Cognitive impairment: Anticholinergics can cause mental confusion and excitement, particularly in elderly patients, even at small doses 1
- Falls risk: Drowsiness, dizziness, and blurred vision increase fall hazard 1
- Urinary retention: Especially problematic in men with prostatic hypertrophy, potentially requiring catheterization 1
- Constipation and ileus: Can precipitate or aggravate serious gastrointestinal complications 1
- Glaucoma exacerbation: Increased intraocular pressure is a significant concern in patients over 40 years 1
Contraindications Common in Elderly
The FDA label lists multiple conditions prevalent in older adults as requiring cautious use or avoidance 1:
- Autonomic neuropathy
- Glaucoma (increased incidence after age 40)
- Prostatic hypertrophy
- Coronary heart disease, congestive heart failure, arrhythmias
- Chronic lung disease (can cause inspissation of bronchial secretions)
- Hepatic and renal disease
Evidence-Based Alternatives for Elderly Patients
For Patients WITHOUT Dementia
First-line approach: Non-pharmacologic interventions 4:
- High-density nutritional supplements and fortified foods
- Dietary counseling with nutritionist referral
- Address reversible causes: dental problems, dysphagia, medication review
- Environmental modifications: supervised meals, verbal prompting, feeding assistance
If pharmacologic intervention needed 4:
- Mirtazapine 30 mg daily (first choice, especially with comorbid depression): Mean weight gain ~2 kg at 3 months; monitor for sedation 4
- Megestrol acetate (second-line): Mixed evidence; risk of thromboembolic events and may impair functional recovery in rehabilitation patients 5, 4
For Patients WITH Dementia
Absolutely no pharmacologic appetite stimulants should be used 6, 4. The 2024 ESPEN guidelines achieved 89% consensus that drugs to stimulate appetite or weight gain should NOT be used in persons with dementia due to inconsistent benefits and potentially harmful side effects 7, 6.
- Feeding assistance and supervision
- Environmental modifications
- Addressing nutrition-impact symptoms
- Oral care to maintain eating function
Clinical Algorithm
- Screen for dementia first → If present, stop here; use only non-pharmacologic measures 4
- Comprehensive medication review → Discontinue appetite-suppressing drugs 4
- Identify reversible causes: pain, depression, dental issues, dysphagia 4
- Implement non-pharmacologic strategies for 2-4 weeks 4
- If inadequate response in non-demented patients:
- Monitor weekly weights; discontinue if no benefit after 6-12 weeks 4
Key Safety Pitfalls
- Never use anticholinergic agents like buclizine in elderly patients due to high risk of delirium, falls, urinary retention, and other serious adverse effects 1
- Never use any appetite stimulant in dementia patients, regardless of weight loss severity 6, 4
- Never prescribe appetite stimulants as first-line without addressing underlying causes 4
- Avoid megestrol acetate during physical rehabilitation as it may impede functional gains 4